EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review

Joseph Sassine iD, Emily A Siegrist, Roy F Chemaly

Viruses · 2025

DOI: 10.3390/v17010133 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2025. Verfasst von Joseph Sassine und 2 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Receptors, Chimeric Antigen, Herpesviridae Infections, Immunotherapy, Adoptive. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this narrative review, we explore the burden and risk factors of various herpesvirus infections in patients receiving chimeric antigen receptor T-cell (CAR-T) therapy or bispecific antibodies (BsAb) for the treatment of hematologic malignancies. Antiviral prophylaxis for herpes simplex/varicella zoster viruses became part of the standard of care in this patient population. Breakthrough infections may rarely occur, and the optimal duration of prophylaxis as well as the timing of recombinant zoster immunization remain to be explored. Clinically significant cytomegalovirus (CMV) infections can affect up to 10% of patients after CAR-T, depending on the CAR-T product target, post-CAR-T complications such as cytokine release syndrome and the need for glucocorticoid therapy. Surveillance and prophylactic strategies for CMV need to be developed, whereas the risk factors for and the burden of CMV infections after BsAb are not yet well-defined. Human herpes virus 6 reactivation and end organ disease such as encephalitis are rarely reported after CAR-T and have not yet been reported after BsAb; additional research is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificReceptors, Chimeric AntigenHerpesviridae InfectionsImmunotherapy, AdoptiveHumansHematologic NeoplasmsCytomegalovirus InfectionsRisk Factors

Stichwörter der Autor:innen

CAR T cell therapyCMVHHV-6HSVVZVbispecific antibodiesherpesviruses

Substanzen

Antibodies, BispecificReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Infectious Diseases Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
  • Department of Pharmacy, OU. Health, Oklahoma City, OK 73104, USA.
  • Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

ORCID-Profile: Joseph Sassine

Zitieren

APA

Sassine, J., Siegrist, E. A., & Chemaly, R. F. (2025). Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review. Viruses. https://doi.org/10.3390/v17010133

Vancouver

Sassine J, Siegrist EA, Chemaly RF. Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review. Viruses. 2025. doi:10.3390/v17010133

BibTeX
@article{Sassine2025,
  author = {Sassine, Joseph and Siegrist, Emily A and Chemaly, Roy F},
  title = {Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17010133}
}
Kostenlos starten →